On the basis of diagnosis, Pyruvate Kinase Deficiency Disease market can be classified into
- Bilirubin in the blood
- Complete Blood Count (CBC)
- Genetic Testing
- Haptoglobin Blood Test
- Osmotic Fragility
- Pyruvate Kinase Activity
- Stool Urobilinogen
The standard diagnostic test for PKD is to measure the activity of the pyruvate kinase enzyme in red blood cells. Low activity of this enzyme is indictive of the disorder. Molecular genetic testing helps to confirm a diagnosis of PKD. Molecular genetic testing can detect mutations in the PKLR gene known to cause the disorder.
These tests are only run at specialized laboratories; most clinics and hospitals send this test to be run at these specialized centres.
In terms of treatment, Pyruvate Kinase Deficiency Disease market can be classified into
- Blood transfusion
- Bone marrow transplantation
- Folic Acid
- Vitamin B
- Iron Chelation
- Allogenic hematopoietic Stem Cell Transplantation (HSCT)
Treatment may require the coordinated efforts of a team of specialists. Symptoms vary between patients so an individualized treatment plan should be developed. Genetic counselling is recommended for affected individuals and their families. In infants, children, and adults with PKD, blood transfusions may be used. The decision to transfuse is not based on the level of hemoglobin, but, rather, how an individual is tolerating the hemolytic anemia. Sometimes, the surgical removal of the spleen (splenectomy) may be recommended. Removal the spleen may be considered if individuals require frequent blood transfusions or have frequent symptoms from anemia. Supportive care can include gallbladder monitoring due to risk of gallstones. Gallbladder removal (cholecystectomy) is pursued in individuals with symptomatic gallstones and in individuals at the time of splenectomy. Folic acid supplementation, which supports increased red cell production, is often prescribed. Vitamin D, calcium, and exercise may be important for bone health. n allogeneic stem cell transplantation, affected individuals, after treatment with chemotherapy, receive hematopoietic stem cells from a healthy donor. This is a major medical procedure that carries significant risk, including dying from complications related to transplant.
By Distribution of Channel:
On the basis of distribution channel, the Pyruvate Kinase (PK) Deficiency Disease market is segmented into hospital pharmacy, retail pharmacy and online pharmacy.
Top Major Players
The Pyruvate Kinase Deficiency Disease Therapeutics market is less competitive with a smaller number of competitors and major key players are adopting strategies such as mergers and acquisitions, partnerships, and regional expansion along with increased focus on R&D to stand out as strong competitors in the market The prominent key players are Sanofi-Aventis Healthcare Pty Ltd., Teva Pharmaceuticals, Baxter Healthcare Pty Ltd., Bayer Australia Ltd., Mylan Health Pty Ltd. are among others.